Polymyalgia Rheumatica and Giant Cell Arteritis

Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are two closely related inflammatory conditions that predominantly affect adults over age 50, with incidence rising sharply after age 70. PMR produces severe aching and stiffness in the shoulder girdle, hip girdle, and neck, while GCA is a systemic vasculitis targeting medium and large arteries — most critically the branches of the external carotid. The two conditions overlap in roughly 15–20% of patients, according to published epidemiological data from the American College of Rheumatology (ACR), making accurate differential diagnosis essential. Understanding their shared biology, distinct presentations, and treatment thresholds is foundational to the broader study of rheumatology conditions covered on this site.

Definition and Scope

PMR and GCA occupy distinct but overlapping diagnostic categories within the vasculitis and inflammatory spectrum described in rheumatology's regulatory and clinical framework. The ACR and the European Alliance of Associations for Rheumatology (EULAR) jointly published classification criteria for both conditions — the 2012 ACR/EULAR PMR classification criteria and the 1990 ACR classification criteria for GCA — providing standardized diagnostic thresholds used in clinical and research settings.

Polymyalgia Rheumatica is defined as a clinical syndrome of bilateral proximal aching and morning stiffness lasting at least 45 minutes, accompanied by elevated inflammatory markers (erythrocyte sedimentation rate [ESR] ≥40 mm/hr or elevated C-reactive protein [CRP]), and rapid, dramatic response to low-dose corticosteroids. It is not an autoimmune disease in the classic sense — antinuclear antibody (ANA) and rheumatoid factor (RF) tests are typically negative.

Giant Cell Arteritis (also called temporal arteritis) is a granulomatous vasculitis of large and medium vessels. It carries a risk of permanent vision loss in up to 20% of untreated cases, primarily through ischemia of the ophthalmic or posterior ciliary arteries, as documented in ACR clinical practice guidance. Temporal artery biopsy remains the diagnostic gold standard, with a sensitivity of approximately 85–90% for a positive specimen of adequate length (≥2 cm per ACR/EULAR recommendations).

How It Works

Both conditions share a common immunopathological substrate: dysregulated innate and adaptive immune responses in aging tissue. In GCA, CD4+ T helper cells — particularly Th1 and Th17 subsets — are recruited into arterial walls, where they drive granuloma formation, intimal hyperplasia, and ischemia. Dendritic cells in the adventitia act as primary antigen-presenting sentinels, a mechanism described in detail in peer-reviewed literature published through the National Institutes of Health (NIH) PubMed database.

In PMR, the dominant pathology is synovitis and bursitis of the proximal joints (subacromial, subdeltoid, trochanteric, and iliopsoas bursae), visible on musculoskeletal ultrasound or MRI. Positron emission tomography with CT (PET-CT) can reveal subclinical large-vessel vasculitis in PMR patients, blurring the clinical boundary between the two diagnoses.

Key laboratory markers in both conditions:

  1. ESR — typically >40 mm/hr in PMR; often >100 mm/hr in active GCA
  2. CRP — elevated in both; more sensitive than ESR in early disease
  3. Interleukin-6 (IL-6) — elevated in both; mechanistically linked to the systemic inflammatory response
  4. Complete blood count — normochromic normocytic anemia and thrombocytosis are common in active GCA
  5. Alkaline phosphatase — mildly elevated in a subset of PMR patients, a finding noted in ACR educational materials

Common Scenarios

The most clinically urgent presentation is new-onset temporal headache, jaw claudication, or scalp tenderness in a patient over age 50 — symptoms that should prompt same-day evaluation for GCA given the risk of irreversible vision loss. The ACR Fast Track pathway, promoted through ACR quality initiatives, recommends ophthalmology and rheumatology assessment within 24 hours for suspected GCA with visual symptoms.

PMR most commonly presents as bilateral shoulder pain and stiffness that is worst in the morning, severe enough to prevent raising the arms above shoulder height, developing over weeks to months. Patients frequently report difficulty rising from a chair, pointing to hip girdle involvement. The condition is the most common inflammatory rheumatic disease in adults over 50 in Northern Europe and North America, with an annual incidence of approximately 52 per 100,000 people aged ≥50 in the United States (source: ACR/EULAR published epidemiologic review data).

GCA without cranial symptoms — termed large-vessel GCA (LV-GCA) — can present as unexplained fever, weight loss, elevated inflammatory markers, and limb claudication. This subset is increasingly recognized through PET-CT imaging.

Decision Boundaries

Distinguishing PMR from GCA and from mimicking conditions requires structured criteria application.

PMR vs. GCA:
- PMR alone: proximal stiffness, no cranial symptoms, normal temporal artery exam, ESR typically 40–80 mm/hr, responds to prednisone 15–20 mg/day
- GCA with PMR overlap: cranial symptoms or visual changes present, ESR often >50 mm/hr, requires higher initial prednisone dose (40–60 mg/day for GCA without visual threat; 500–1000 mg IV methylprednisolone for sight-threatening GCA, per ACR/EULAR 2021 GCA recommendations)

PMR vs. mimics — conditions that must be excluded before confirming PMR diagnosis:
- Rheumatoid arthritis (positive RF/anti-CCP, peripheral joint involvement)
- Vasculitis syndromes (systemic features, skin/renal involvement)
- Hypothyroidism (TSH testing required)
- Malignancy (constitutional symptoms, inadequate corticosteroid response)
- Inflammatory myopathies (elevated creatine kinase, proximal weakness rather than stiffness)

Tocilizumab (an IL-6 receptor antagonist) received FDA approval specifically for GCA in 2017, representing the first biologic therapy approved for this condition. The ACR/EULAR 2021 GCA management recommendations support tocilizumab use alongside glucocorticoids to reduce cumulative steroid exposure.

Relapse rates in PMR reach approximately 40–50% during or after corticosteroid tapering, underscoring the need for structured monitoring protocols aligned with ACR guidance.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)